Menu
No results found.
STX
Shield Therapeutics plc – LSE
Weekly Share Price & Valuation Overview
Market Overview
Open
5.5500
Close
5.6500
High
5.8000
Low
5.5000
Trend
0.69015
Shield Therapeutics plc
United Kingdom
• LSE - London Stock Exchange
• STX
• Currency: GBp
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Key strengths
- Earnings growth ≥10% supports improving profitability trajectory.
Potential weaknesses
- Negative free cash flow — operations may rely on external financing.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares. Revenue estimated from Revenue/share × Shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- GBp 58.86M
- Enterprise Value Operating value: market cap + total debt − cash.
- GBp 78.70M
- Total Revenue (TTM) Estimated Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- GBp 42.71M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- GBp 14.93M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- GBp -22.38M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- GBp 0.04
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.02
- Shares Outstanding
- 1.04B
- Float Shares
- 385.77M
- Implied Shares Outstanding
- 1.04B
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-43.97%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
-52.41%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
34.96%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-84.47%
- ROA Return on assets: net income ÷ total assets.
-
-26.90%
- ROE Return on equity: net income ÷ shareholder equity.
-
-3.96%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Year-over-year revenue growth.
-
1.15%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).
- 0.90
- Total Cash Cash and equivalents.
- GBp 6.52M
- Total Debt Short + long-term interest-bearing debt.
- GBp 26.37M
- Net Debt Total debt − cash (negative = net cash).
- GBp 19.85M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- -1.18
Cash Flow
Shown only when internally consistent; margins are TTM.
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- GBp -6.77M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- GBp -12.05M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-15.85%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-28.21%
- Cash Conversion (OpCF/EBITDA)
- 0.30
Sharemaestro House View
Confidence: 2
Sharemaestro internal conviction (0–3, higher is better).
Risk: 1
Sharemaestro internal risk profile (0–3, higher is safer).
Composite Score: 2
Overall internal composite (0–3, higher is better).
Suggested Allocation: 3.33%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
37.0%
Insiders
Shares held by company insiders (officers, directors).
73.3%
Institutions
Shares held by institutions (funds, pensions).
2.2%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
None detected
Net Debt
Total debt − cash (negative = net cash).
GBp 19.85M
46.5% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
47
Methodology Notes
- Total Revenue (TTM) estimated from Revenue per Share × Shares due to feed inconsistency.
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 03:52
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.